Risk for cardiovascular event was similar in patients who stopped/interrupted therapy (OR, 0.70; P=.352) or had early cessation (OR, 1.04; P=.876) compared with persistent users.

Study design

194 patients with acute ischemic stroke and 776 matched control patients were analyzed for the effects of stopping/interrupting antiplatelet therapy (used for >3 d, stopped prior to 90 d), early cessation (used for <3 d), and persistent use (used for >3 d, continued up to 90 d).

Funding: Ministry of Health, Government of Malaysia Scholarship.

Limitations

Lack of information on reasons for discontinuation.

Limited study power due to small patient sample size.

Only healthcare professionals with a Univadis account have access to this article.

This site uses cookies to run smoothly, personalise your experience and provide you relevant promotions. To learn more about the cookies on this site, including how to manage them, click here . Otherwise, we’ll assume you’re OK to continue. Learn more.

Univadis will update its Terms of Use and Privacy Policy on January 12, 2016. Please contact privacy@aptushealth.com if you have any questions about these changes. If you continue to use Univadis after January 12, 2016 the new Terms of Use and Privacy Policy will apply. By your continued use of Univadis, you accept and agree to these terms and policies.